secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001193125-22-300141
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phoenix Biotech Acquisition Corp. and Intrinsic Medicine mutually terminate business combination agreement
--------------------------------------------------------------------------------

- Business combination agreement terminated on December 6, 2022 due to current market conditions.
- No termination fee or other payment due from any party as a result of the termination.
- Sponsor support agreement and intrinsic support agreements automatically terminated.
- PBAX CEO Chris Ehrlich expressed continued optimism about Intrinsic's platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/d421267d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-300141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer